← Back to Melanoma

Melanoma Clinical Trials: Should You Consider One?

What clinical trials are, who they're for, and how to find one that fits your care

Medically reviewed by Dr. Steven Q. Wang, MDLast reviewed

Bring a printable list of questions to your appointment, or share this page with someone who needs it.

Download checklist (PDF)

Introduction

When a doctor first mentions "clinical trial," it can sound like a sign that things have taken a turn for the worse. For many patients, the word conjures images of a last-ditch experiment tried only after everything else has failed. In melanoma care, that picture is largely outdated. Clinical trials are how today's standard treatments—checkpoint inhibitors, BRAF/MEK-targeted therapy, combination immunotherapy—became standard in the first place, and they remain one of the main ways doctors continue to improve outcomes for advanced and metastatic melanoma.

This guide explains what a clinical trial actually involves, clears up common misconceptions, and walks through how to find and evaluate a trial that might fit your situation.

Have Questions?

Ask questions and get clear, trusted answers — instantly.

Chat with the Navigator

What Is a Clinical Trial, and What Are the Phases?

A clinical trial is a carefully designed research study that tests a new drug, combination of drugs, or treatment approach in people, to find out whether it's safe and whether it works better than—or as well as—existing options. Every trial follows a written protocol that specifies who can enroll, what treatment participants receive, and what will be measured.

Cancer treatment trials move through four phases, each answering a different question:

  • •Phase I — Is it safe, and what's the right dose? Usually the smallest trials (a few dozen participants), often open to patients whose melanoma has progressed on standard therapies.
  • •Phase II — Does it work? Researchers look for early evidence of effectiveness in a specific type or stage of melanoma, while continuing to monitor safety.
  • •Phase III — Is it better than (or as good as) the current standard of care? Larger trials, often randomized, that compare the new approach directly against existing treatment. Many of melanoma's current standard therapies were established through Phase III trials.
  • •Phase IV — What happens over the long run? Conducted after a treatment is already approved, to track long-term safety and effectiveness in larger, more diverse patient populations.

Common Misconceptions About Clinical Trials

"Trials are a last resort, for when nothing else has worked."

This is the misconception patients report most often—and research on cancer trial enrollment confirms the gap: patients are far more likely than physicians and research staff to believe trials are only offered when a case is "hopeless." In reality, many melanoma trials are designed for patients earlier in their care, testing new immunotherapy or targeted-therapy combinations for advanced or metastatic diseasebefore standard options have been exhausted, or even as an initial treatment alongside surgery.

"I might get a placebo instead of real treatment."

Placebo-only arms are rare in cancer research and considered unethical whenever an effective standard treatment exists. Most melanoma trials compare a new treatment against the current standard of care, or add the new treatment on top of standard care—so participants who don't receive the experimental therapy still receive appropriate, guideline-based treatment.

"Once I join, I'm locked in."

Participation is entirely voluntary. You can withdraw at any point, for any reason, without it affecting your access to standard medical care going forward.

Who Might Be a Candidate?

Every trial has its own eligibility criteria, but candidacy for a melanoma trial often depends on factors such as:

  • •Stage and extent of disease — many trials specifically target advanced (stage III unresectable) or metastatic (stage IV) melanoma; others focus on high-risk resected melanoma in the adjuvant setting.
  • •Prior treatment history — some trials are open only to patients who haven't yet received systemic therapy, while others specifically enroll patients whose melanoma progressed after immunotherapy or targeted therapy.
  • •Tumor mutation status — trials of BRAF/MEK inhibitors or other targeted agents typically require confirmed BRAF (or other) mutations from your pathology report or molecular testing.
  • •Overall health and organ function — most trials require adequate blood counts, kidney and liver function, and a reasonable performance status (a measure of how well you can carry out daily activities).

There's no single profile of "who qualifies"—a newly diagnosed patient, someone with recurrent melanoma, and someone whose disease has spread widely could each be a fit for different trials. The only reliable way to know is to ask your care team or search directly using the eligibility criteria of specific trials.

How Trials Fit Alongside Standard Treatment

A clinical trial isn't necessarily an alternative to standard care—it's often layered into it. Trials may test:

  • •New combinations of existing immunotherapy and targeted-therapy drugs, aiming to improve response rates beyond what either drug achieves alone—see our overview of current melanoma treatment options for how these drug classes are already used.
  • •Neoadjuvant approaches, giving immunotherapy before surgery to shrink a tumor or reduce recurrence risk.
  • •Adjuvant approaches, adding a new therapy after surgery for high-risk, node-positive, or resected stage III/IV melanoma—stage is central to this decision; see what your melanoma stage means.
  • •Newer modalities such as personalized mRNA vaccines, tumor-infiltrating lymphocyte (TIL) therapy, and oncolytic virus therapy, usually studied in combination with an approved checkpoint inhibitor.

Your oncologist can help map out where, if at all, a trial might slot into your overall treatment plan—sometimes as the primary treatment, sometimes as a next step if standard therapy stops working, and sometimes as an added option alongside it.

Informed Consent and Safety Monitoring

Every clinical trial in the U.S. must be reviewed and approved by an independent Institutional Review Board (IRB) before it can enroll a single patient. The IRB's job is to weigh the potential benefits against the risks and confirm that the trial is designed and monitored ethically.

Before you enroll, the research team walks you through an informed consentdocument that explains the trial's purpose, procedures, known risks and possible benefits, alternative treatments available to you, and your right to leave the trial at any time. You're encouraged to take the document home, discuss it with family, and ask as many questions as you need before signing—and you can withdraw your consent later, even after enrolling.

Once enrolled, many trials are also overseen by a Data and Safety Monitoring Board (DSMB), an independent group that periodically reviews accumulating safety data and can pause or stop a trial early if a safety concern emerges.

How to Find a Melanoma Clinical Trial

  • •ClinicalTrials.gov— the federal registry of essentially every clinical trial conducted in the U.S. and many international sites. You can filter by melanoma, stage, location, and recruitment status, though the eligibility criteria can be dense and clinical.
  • •National Cancer Institute (NCI)— NCI's melanoma clinical trials search tool, which pulls from the same underlying registry but with a more patient-friendly interface.
  • •Melanoma Research Alliance— a guided Clinical Trial Navigator that matches you to potentially eligible trials by asking about your diagnosis, stage, and treatment history.
  • •AIM at Melanoma Foundation— plain-language explanations of how trials work plus a patient navigator service that can help identify appropriate studies.
  • •Academic melanoma centers — NCI-Designated Comprehensive Cancer Centers and large academic melanoma programs typically run their own trial portfolios and are often the fastest way to learn what's actively enrolling near you; ask your dermatologist or oncologist for a referral if your community practice doesn't have trials open.

What to Ask Your Doctor Before Enrolling

Download printable checklist (PDF)
  • •Is there a clinical trial that fits my specific diagnosis and stage?
  • •What phase is this trial in, and what does that mean for how well the treatment's safety and effectiveness are already understood?
  • •What are the known and possible side effects, and how will they be monitored?
  • •Will I still receive standard treatment, or does the trial replace it?
  • •What extra tests, visits, or time commitments does participation require compared with standard care?
  • •What happens if the trial treatment doesn't work for me, or if I want to stop participating?
  • •Are travel, lodging, or costs of trial-related care covered, and what will my insurance still need to pay for?

Conclusion

A clinical trial isn't a sign that your care team has given up on standard options—it's often a way to access tomorrow's treatment today, under close medical supervision and with protections built in at every step. Whether or not a trial ends up being right for you, it's worth asking your dermatologist or oncologist early, not just as a last resort, so you understand the full range of options available for your specific melanoma.

→ Learn more at: BeatingSkinCancer.com/melanoma

Sources

Clinical Guidelines & Peer-Reviewed Literature

  • Swetter SM, Johnson D, Albertini MR, et al. Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(6):272-277. PubMed
  • Hillyer GC, Beauchemin M, Hershman DL, et al. Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients. Clin Trials. 2020;17(2):184-194. PubMed
  • Wróbel S, Przybyło M, Stępień E. The Clinical Trial Landscape for Melanoma Therapies. J Clin Med. 2019;8(3):368. PubMed

Patient Resources

Disclaimer: Educational only. Not a substitute for professional medical advice. Always consult your dermatologist or oncologist about your personal diagnosis and treatment plan.

Still Have Questions?

Chat with our AI guide for personalized information about melanoma clinical trials

Chat with the Navigator